Advances in the Development of Mitochondrial Pyruvate Carrier Inhibitors for Therapeutic Applications DOI Creative Commons

Henry Politte,

Lingaiah Maram, Bahaa Elgendy

и другие.

Biomolecules, Год журнала: 2025, Номер 15(2), С. 223 - 223

Опубликована: Фев. 3, 2025

The mitochondrial pyruvate carrier (MPC) is a transmembrane protein complex critical for cellular energy metabolism, enabling the transport of from cytosol into mitochondria, where it fuels citric acid cycle. By regulating this essential entry point carbon MPC pivotal maintaining balance and metabolic flexibility. Dysregulation activity has been implicated in several disorders, including type 2 diabetes, obesity, cancer, underscoring its potential as therapeutic target. This review provides an overview complex, examining structural components, regulatory mechanisms, biological functions. We explore current understanding transcriptional, translational, post-translational modifications that modulate function highlight clinical relevance dysfunction neurodegenerative diseases. Progress development MPC-targeting therapeutics discussed, with focus on challenges designing selective potent inhibitors. Emphasis placed modern approaches identifying novel inhibitors, particularly virtual screening computational strategies. establishes foundation further research medicinal chemistry promoting advances structure-based drug design to develop

Язык: Английский

Advances in the Development of Mitochondrial Pyruvate Carrier Inhibitors for Therapeutic Applications DOI Creative Commons

Henry Politte,

Lingaiah Maram, Bahaa Elgendy

и другие.

Biomolecules, Год журнала: 2025, Номер 15(2), С. 223 - 223

Опубликована: Фев. 3, 2025

The mitochondrial pyruvate carrier (MPC) is a transmembrane protein complex critical for cellular energy metabolism, enabling the transport of from cytosol into mitochondria, where it fuels citric acid cycle. By regulating this essential entry point carbon MPC pivotal maintaining balance and metabolic flexibility. Dysregulation activity has been implicated in several disorders, including type 2 diabetes, obesity, cancer, underscoring its potential as therapeutic target. This review provides an overview complex, examining structural components, regulatory mechanisms, biological functions. We explore current understanding transcriptional, translational, post-translational modifications that modulate function highlight clinical relevance dysfunction neurodegenerative diseases. Progress development MPC-targeting therapeutics discussed, with focus on challenges designing selective potent inhibitors. Emphasis placed modern approaches identifying novel inhibitors, particularly virtual screening computational strategies. establishes foundation further research medicinal chemistry promoting advances structure-based drug design to develop

Язык: Английский

Процитировано

0